This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of the Claims

1-48. (canceled)

49. (previously presented) An inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml.

50. (currently amended) The inclusion complex of claim [[1]] 49 wherein the molar ratio of the cyclodextrin to the modafinil compound is from about 10:1 to about 0.8:1.

51. (currently amended) The inclusion complex of ~~claims 1 or 2~~ claim 49 wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, dimethyl-β-cyclodextrin, trimethyl-β-cyclodextrin, 2-hydroxymethyl-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, 3-hydroxypropyl-β-cyclodextrin, β-cyclodextrin sulfate, β-cyclodextrin sulfonate, or β-cyclodextrin sulfobutyl ether.

52. (currently amended) The inclusion complex of claim [[3]] 51 wherein the modafinil compound is modafinil and the cyclodextrin is a β-cyclodextrin.

53. (currently amended) The inclusion complex of claim [[4]] 52 wherein the modafinil compound is the levorotatory form of modafinil.

54. (currently amended) The inclusion complex of ~~claim 54~~ claims 52 or 53 wherein the cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.

55. (currently amended) The inclusion complex of claim [[2]] 50 wherein the molar ratio of the cyclodextrin to the modafinil compound is about 4:1.

56. (currently amended) The inclusion complex of claim [[7]] 55 wherein

the molar ratio of the cyclodextrin to the modafinil compound is about 1:1.

57. (currently amended) The inclusion complex of claim [[1]] 49 wherein the modafinil compound has an aqueous solubility of at least 20 mg/ml.

58. (previously presented) A pharmaceutical composition comprising an inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml.

59. (currently amended) The composition of claim [[10]] 58 wherein the modafinil compound has an aqueous solubility of at least 20 mg/ml.

60. (currently amended) The composition of claim [[10]] 58 wherein the molar ratio of the cyclodextrin to the modafinil compound is from about 10:1 to about 0.8:1.

61. (currently amended) The composition of claim [[12]] 60 wherein the molar ratio of the cyclodextrin to the modafinil compound is about 4:1.

62. (currently amended) The composition of claim [[13]] 61 wherein the molar ratio of the cyclodextrin to the modafinil compound is about 1:1.

63. (currently amended) The composition of claim [[10]] 58 wherein the composition provides at least a 25% increase in the blood serum level of a modafinil compound in a mammal upon oral administration ~~of a modafinil compound to a mammal~~ relative to a solid dose of a modafinil compound.

64. (currently amended) The composition of claim [[15]] 58 wherein the composition provides at least a 50% increase in the blood serum level of a modafinil compound in a mammal within the first hour of oral administration relative to a solid dose of a modafinil compound.

65. (currently amended) The ~~compositions~~ composition of claims [[15 or 16]] 63 or 64 wherein the composition is in a solution form.

66. (currently amended) The composition of claim [[10]] 58 wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, dimethyl-β-cyclodextrin, trimethyl-β-cyclodextrin, 2-hydroxymethyl-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, 3-hydroxypropyl-β-cyclodextrin, β-cyclodextrin sulfate, β-cyclodextrin sulfonate, or β-cyclodextrin sulfobutyl ether.

67. (currently amended) The composition of claim [[18]] 66 wherein the modafinil compound is modafinil and the cyclodextrin is a β-cyclodextrin.

68. (currently amended) The composition of claim [[19]] 67 wherein the modafinil compound is the levorotatory form of modafinil.

69. (currently amended) The composition of ~~claim 20~~ claims 67 or 68 wherein the cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.

70. (currently amended) The composition of claim [[20]] 67 wherein the composition comprises modafinil in an aqueous 50% 2-hydroxypropyl-β-cyclodextrin solution.

71. (currently amended) The composition of claim [[10]] 58 which has substantially the blood serum profile of FIG. 1.

72. (currently amended) The composition of claim [[10]] 58 wherein the composition is in a solution form.

73. (currently amended) The composition of claim [[24]] 72 wherein the composition is aqueous and suitable for oral consumption.

74. (currently amended) The composition of claim [[24]] 72 wherein the

composition is a syrup or elixir.

75. (currently amended) The composition of claim [[10]] 58 wherein the composition is in a solid form.

76. (currently amended) The composition of claim [[27]] 75 wherein the composition is in the form of a tablet or a capsule.

77. (currently amended) The composition of claim [[10]] 58 comprising one or more unit doses of modafinil.

78. (currently amended) The composition of claim [[29]] 77 comprising one unit dose of modafinil.

79. (currently amended) The composition of claim [[30]] 78 wherein the unit dose is 200 mg of modafinil.

80. (currently amended) The composition of claim [[30]] 78 wherein the unit dose is 100 mg of modafinil.

81. (currently amended) The composition of claim ~~10, 19, or 20~~ 58, 67, or 68 wherein the modafinil compound is taste-masked.

82. (currently amended) The composition of claim [[33]] 81 wherein the composition is a syrup or elixir.

83. (previously presented) A method of preparing an inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml comprising contacting the modafinil compound with the cyclodextrin in an aqueous medium.

84. (currently amended) The method of claim [[35]] 83 wherein the

inclusion complex is dried and isolated as a solid.

85. (previously presented) A method of treating a disease or disorder in a subject, comprising administering a therapeutically effective amount of a composition of a modafinil compound and a cyclodextrin to a subject.

86. (currently amended) The method of claim [[37]] 85 wherein the composition is administered for the treatment of sleepiness, tiredness, Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, attention deficit hyperactivity disorder, cognitive dysfunction or fatigue; and for the promotion of wakefulness, stimulation of appetite, or stimulation of weight gain.

87. (currently amended) The method of claim [[38]] 86 wherein the composition is administered orally.